Valganciclovir Hydrochloride For Solution
NDC Package 70069-810-01
Package Information
Valganciclovir Hydrochloride (valganciclovir) for solutions is valganciclovir hydrochloride is contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valganciclovir, ganciclovir, or any component of the formulation[see Adverse Reactions (6.1)]. This formulation utilizes a for solution delivery system. Marketed by Somerset Therapeutics, Llc, this product is identified by NDC 70069-810 and is authorized under FDA application ANDA213306.
Identification & Billing
- RxCUI: 863559 - valGANciclovir 50 MG in 1 mL Oral Solution
- RxCUI: 863559 - valganciclovir 50 MG/ML Oral Solution
- RxCUI: 863559 - valganciclovir (as valganciclovir hydrochloride) 50 MG/ML Oral Solution
- RxCUI: 863559 - valganciclovir 50 MG per 1 ML Oral Solution
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 70069 - Somerset Therapeutics, Llc
- 70069-810 - Valganciclovir Hydrochloride
- 70069-810-01 - 100 mL in 1 BOTTLE
- 70069-810 - Valganciclovir Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 70069-810-01 identifies a specific commercial package of 100 ml in 1 bottle of Valganciclovir Hydrochloride, a human prescription drug labeled by Somerset Therapeutics, Llc. This for solution is formulated for oral use and contains valganciclovir as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Somerset Therapeutics, Llc on January 15, 2022. The current certification is valid through December 31, 2027.
How is this Somerset Therapeutics, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 70069081001. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.